Novartis: Endometrial Neoplasms trials
The registry lists 13 Endometrial Neoplasms studies with Novartis as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 1 5Phase 2 10(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedNCT02807844Phase 1/2Results posted
- LDE225 for Patients With PTCH1 or SMO Mutated TumorsTerminatedNCT02002689Phase 2Results posted
- A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial CancerCompletedNCT01379534Phase 2Results posted
- BKM120 as Second-line Therapy for Advanced Endometrial CancerCompletedNCT01289041Phase 2Results posted
- Study of CLR457 Administered Orally in Adult Patients With Advanced Solid MalignanciesTerminatedNCT02189174Phase 1
- Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial CarcinomaCompletedNCT01689714Phase 2
- Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial CancerCompletedNCT01686256Phase 1
- BEZ235 Trial in Patients With Advanced Endometrial CarcinomaWithdrawnNCT01290406Phase 2
- Safety of BKM120 Monotherapy in Advanced Solid Tumor PatientsCompletedNCT01068483Phase 1
- Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)CompletedNCT00507741Phase 2
- A Study of Letrozole in the Treatment of Endometrial CancerCompletedNCT00333086Phase 2
- Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial CancerCompletedNCT00171808Phase 2